SIETES :: 92793 citas

Resultados de la búsqueda por ESTRÓGENO + PROGESTÁGENO REFINAR BÚSQUEDA

1.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

2.

Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019;364:6 de marzo. [Ref.ID 103059]

3.

Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol 2019;30:19 de marzo. [Ref.ID 103053]

4.

Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]

5.

Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017;377:2228-39. [Ref.ID 102165]

6.

Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thompson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, for the WHI Investigators. Menopausal Hormone therapy and long-term all-cause and cause-specific mortality. The Women’s Health Initiative randomized trials. JAMA 2017;318:927-38. [Ref.ID 102070]

7.

McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]

8.

Willett WC. Mediterranean diet and fracture risk. JAMA Intern Med 2016;176:652-3. [Ref.ID 100258]

9.

Haring B, Crandall CJ, Wu C, LeBlanc ES, Shikanty JM, Carbone L, Orchard T, Thomas F, Wactawaski-Wende J, Li W, Cauley JA, Wassertheil-Smoller S. Dietary patterns and fractures in postmenopausal women: results from the Women's Health Initiative. JAMA Intern Med 2016;176:645-52. [Ref.ID 100257]

10.

Anónimo. Traitement hormonal substitutif de la ménopause: cancers de l'ovaire. Prescrire 2015;35:671. [Ref.ID 99718]

11.

Anónimo. Éthinylestradiol + gestodène. Prescrire 2015;35:647-8. [Ref.ID 99707]

12.

Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]

13.

Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015;351:h4847. [Ref.ID 99595]

14.

Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385:1835-42. [Ref.ID 99038]

15.

Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE, Speizer FE, Michels KB. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. BMJ 2014;349:g6356. [Ref.ID 98360]

16.

Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial. A modeling study. Ann Intern Med 2014;160:594-602. [Ref.ID 97572]

17.

Anónimo. St John's wort: interaction with hormonal contraceptives, including implants-reduced contraceptive effect. Drug Safety Update 2014;7:A2. [Ref.ID 97242]

18.

Stegeman BH, de Bastos M, Rosendall FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347:1-12. [Ref.ID 96257]

19.

Grodstein F. Hormone therapy in younger women and cognitive health. JAMA Intern Med 2013;173:1437-8. [Ref.ID 95978]

20.

Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBland ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Lane D, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM, WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429-36. [Ref.ID 95976]